Search Results - "HAY, Joel W"

A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L by Hay, Joel W., Gong, Cynthia L., Jiao, Xiayu, Zawadzki, Nadine K., Zawadzki, Roy S., Pickard, A. Simon, Xie, Feng, Crawford, Samuel A., Gu, Ning Yan

“…Background The COVID-19 pandemic has resulted in negative impacts on the economy, population health, and health-related quality-of-life (HRQoL). Objective To…”
Get full text

Predicting panel attrition in longitudinal HRQoL surveys during the COVID-19 pandemic in the US by Yu, Tianzhou, Chen, Jiafan, Gu, Ning Yan, Hay, Joel W, Gong, Cynthia L

“…Online longitudinal surveys may be subject to potential biases due to sample attrition. This study was designed to identify potential predictors of attrition…”
Get full text

Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States by Chen, Christina X, Hay, Joel W

“…Abstract Background/objectives Familial hypercholesterolemia (FH) is a genetic disorder that leads to premature heart disease or stroke if untreated. Statins…”
Get full text

Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey by Thompson, Christin Ann, BS, Hay, Joel W., PhD

“…Abstract Purpose More research is needed on the health effects of marijuana use. Results of previous studies indicate that marijuana could alleviate certain…”
Get full text

Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis by Wei, Yifan, Hay, Joel W, Hay, Alan R, Suen, Sze-Chuan

“…To assess the price range in which fexapotide triflutate (FT), a novel injectable, is cost-effective relative to current oral pharmacotherapy (5 α-reductase…”
Get full text

Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid by Ganapathy, Vaidyanathan, Hay, Joel W, Kim, Jae H, Lee, Martin L, Rechtman, David J

“…Infants who survive advanced necrotizing enterocolitis (NEC) at the time of birth are at increased risk of having poor long term physiological and…”
Get full text

Cost-effectiveness analysis of extended extracorporeal membrane oxygenation duration in newborns with congenital diaphragmatic hernia in the United States by Zheng, Hanke, Gong, Cynthia, Chapman, Rachel, Yieh, Leah, Friedlich, Philippe, Hay, Joel W.

“…The duration of extracorporeal membrane oxygenation (ECMO) has been historically confined in many centers to two weeks. We evaluated the cost-effectiveness of…”
Get full text

Cost‐effectiveness analysis of lapatinib in HER‐2–positive advanced breast cancer by Le, Quang A., Hay, Joel W.

“…BACKGROUND: A recent clinical trial demonstrated that the addition of lapatinib to capecitabine in the treatment of HER‐2–positive advanced breast cancer (ABC)…”
Get full text

Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II by Garrison, Louis P., PhD, Mansley, Edward C., PhD, Abbott, Thomas A., PhD, MBA, Bresnahan, Brian W., PhD, Hay, Joel W., PhD, Smeeding, James, RPh, MBA

“…Abstract Objectives Major guidelines regarding the application of cost-effectiveness analysis (CEA) have recommended the common and widespread use of the…”
Get full text

Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling" by Zawadzki, Nadine K, Hay, Joel W

“…With their article, Grutters et al raise an important question: What do successful health technology assessments (HTAs) look like, and what is their real-world…”
Get full text

Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab by Xu, Yifan, Hay, Joel W, Barzi, Afsaneh

“…The alarming increase in the cost of cancer care is forcing all stakeholders to re-evaluate their approach to treatment. Drugs are the main contributor to the…”
Get full text

Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia by Aponte-González, Johanna, Fajardo-Bernal, Luisa, Diaz, Jorge, Eslava-Schmalbach, Javier, Gamboa, Oscar, Hay, Joel W

“…To compare costs and effectiveness of three strategies used against cervical cancer (CC) and genital warts: (i) Screening for CC; (ii) Bivalent Human…”
Get full text

Marijuana Use in Models for Health Outcomes by Thompson, Christin A., BS, Hay, Joel W., PhD

Get full text

Cost-Effectiveness Analysis of Collaborative Care Management of Major Depression among Low-Income, Predominantly Hispanics with Diabetes by Hay, Joel W., PhD, Katon, Wayne J., MD, Ell, Kathleen, DSW, Lee, Pey-Jiuan, MS, Guterman, Jeffrey J., MD, MS

“…Abstract Objective To evaluate the cost-effectiveness of a socioculturally adapted collaborative depression care program among low-income Hispanics with…”
Get full text

Antidepressant Use in Geriatric Populations: The Burden of Side Effects and Interactions and Their Impact on Adherence and Costs by Mark, Tami L., Ph.D., M.B.A, Joish, Vijay N., Ph.D, Hay, Joel W., Ph.D, Sheehan, David V., M.D., M.B.A, Johnston, Stephen S., M.A, Cao, Zhun, P.h.D

“…Objectives The study aimed to determine the prevalence of documented side effects and drug–drug interactions in older adults using antidepressants and their…”
Get full text

Geographic variation in the use of continuous outpatient inotrope infusion therapy and beta blockers by Grazette, Luanda, Tran, Jeffrey S., Zawadzki, Nadine K., Zawadzki, Roy S., McLeod, Jennifer M., Fong, Michael W., Wilson, Melissa L., Havakuk, Ofer, Hay, Joel W.

“…Continuous outpatient inotrope infusion therapy (COIIT) can be used as palliative or interim treatment in patients with advanced heart failure (AHF). Despite…”
Get full text

Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I by Hay, Joel W., PhD, Smeeding, Jim, RPh, MBA, Carroll, Norman V., RPh, PhD, Drummond, Michael, PhD, Garrison, Louis P., PhD, Mansley, Edward C., PhD, Mullins, C. Daniel, PhD, Mycka, Jack M., BS, Seal, Brian, PhD, RPh, MBA, Shi, Lizheng, PhD, MS

“…Abstract Objectives The assignment of prices or costs to pharmaceuticals can be crucial to results and conclusions that are derived from pharmacoeconomic cost…”
Get full text

First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective by Hu, Xiaohan, Hay, Joel W.

“…•The ICER of pembrolizumab vs. chemotherapy is £86,913/QALY in untreated NSCLC patients•The ICER of pembrolizumab is sensitive to patient utility other than…”
Get full text

Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling by Hay, Joel W.

“…In contrast to many other countries, during the 20 years since the founding of Value in Health, the United States has moved further away from using value-based…”
Get full text

Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial by Meeker, Daniella, Linder, Jeffrey A, Fox, Craig R, Friedberg, Mark W, Persell, Stephen D, Goldstein, Noah J, Knight, Tara K, Hay, Joel W, Doctor, Jason N

“…IMPORTANCE: Interventions based on behavioral science might reduce inappropriate antibiotic prescribing. OBJECTIVE: To assess effects of behavioral…”
Get full text